APRE (Aprea Therapeutics) EPS (Basic): $-1.54 (TTM As of Mar. 2026)


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.80
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics EPS (Basic)?

Aprea Therapeutics APRE -1.03% 30 EPS (Basic) is $-1.54 as of Mar. 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Aprea Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.54.

Aprea Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.54.

Aprea Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.53.

During the past 3 years, the average EPS without NRI Growth Rate was 55.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 52.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Aprea Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 59.30% per year. The lowest was -30.20% per year. And the median was 47.40% per year.

Aprea Therapeutics  (NAS:APRE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aprea Therapeutics EPS (Basic) Related Terms

Aprea Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics EPS (Basic) Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -34.88 -67.99 -3.95 -2.35 -1.93

Aprea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.53 -0.47 -0.32 -0.22
APRE
30GF Score
Aprea Therapeutics Inc APRE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Aprea Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-12.6-0)/6.539
=-1.93

Aprea Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.288-0)/14.685
=-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.54 mean?
Aprea Therapeutics (APRE) has a EPS (Basic) of $-1.54 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aprea Therapeutics and its competitors.
Is Aprea Therapeutics' EPS (Basic) too high?
Aprea Therapeutics' current EPS (Basic) is $-1.54. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' EPS (Basic) compare to JUNS and KAPA?
Aprea Therapeutics' EPS (Basic) of $-1.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current EPS (Basic) is $-1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current EPS (Basic) of $-1.54. The current EPS (Basic) is $-1.54. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current EPS (Basic) is $-1.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.80
Price